Recordati : Un T3 au-dessus des attentes, guidance 2022 relevée
>Les maladies rares en fer de lance - Recordati a publié hier en cours de bourse ses résultats T3 2022 et ceux-ci ressortent nettement au-dessus des attentes. Les ventes, en croissance de 26% à 485 M€ (+8% vs Cs), continuent d’être orientées par la bonne dynamique de la franchise maladies rares (+72% yoy à 169 M€) notamment sous l’effet de 1/ la franchise Endo (Signifor et Isturisa / +40% ytd) et 2/ l’intégration du portefeuille oncologie d’EUSA (91 M€ depuis son incl...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.